# Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

> **NCT03920215** · PHASE2,PHASE3 · COMPLETED · sponsor: **Oyster Point Pharma, Inc.** · enrollment: 101 (actual)

## Conditions studied

- Long Term Follow up Dry Eye Disease

## Interventions

- **DRUG:** OC-01 Low Dose, 0.12 mg/mL
- **DRUG:** OC-01 Mid Dose, 0.6 mg/mL
- **DRUG:** OC-01 High Dose, 1.2 mg/mL
- **DRUG:** Placebo (vehicle) nasal spray

## Key facts

- **NCT ID:** NCT03920215
- **Lead sponsor:** Oyster Point Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-15
- **Primary completion:** 2019-09-20
- **Final completion:** 2019-09-20
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2023-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03920215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03920215, "Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03920215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*